| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/17455057.5.2.135 |
| P698 | PubMed publication ID | 19245352 |
| P2093 | author name string | Charles E Geyer | |
| Bushra Haq | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy | Q28593656 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. | Q31960126 | ||
| Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial | Q33724456 | ||
| The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities | Q34399306 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors | Q36334739 | ||
| Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts | Q40318915 | ||
| Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. | Q40335378 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer | Q40554269 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. | Q42627458 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm | Q44529239 | ||
| The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. | Q44618276 | ||
| Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients | Q46464385 | ||
| Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 | ||
| Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients | Q46580491 | ||
| HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 | ||
| HER-2 testing in breast cancer using parallel tissue-based methods | Q47685189 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| P433 | issue | 2 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 135-147 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Women's Health | Q15762155 |
| P1476 | title | Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer | |
| P478 | volume | 5 |
| Q37699356 | Stem cells of the breast and cancer therapy | cites work | P2860 |
Search more.